Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K beta inhibitors
Certal, V., Halley, F., Virone-Oddos, A., Thompson, F., Filoche-Romme, B., El-Ahmad, Y., Carry, J.C., Delorme, C., Karlsson, A., Abecassis, P.Y., Vincent, L., Bonnevaux, H., Nicolas, J.P., Morales, R., Michot, N., Vade, I., Louboutin, A., Perron, S., Doerflinger, G., Tric, B., Monget, S., Lengauer, C., Schio, L.(2012) Bioorg Med Chem Lett 22: 6381-6384
- PubMed: 22981333
- DOI: https://doi.org/10.1016/j.bmcl.2012.08.072
- Primary Citation of Related Structures:
4G11 - PubMed Abstract:
From a HTS campaign, a new series of pyrimidone anilides exemplified by compound 1 has been identified with good inhibitory activity for the PI3Kβ isoform. The structure of compound 1 in PI3Kγ was solved revealing a binding mode in agreement with the SAR observed on PI3Kβ. These compounds displayed inhibition in the nanomolar range in the biochemical assay and were also potent p-Akt inhibitors in a PTEN-deficient PC3 prostate cancer cell line. Optimization of in vitro pharmocokinetic properties led to compound 25 exhibiting 52% bioavailability in mice and target engagement in an acute PK/PD study.
Organizational Affiliation:
Medicinal Chemistry Oncology Drug Discovery, Sanofi, Vitry-sur-Seine, France.